PETVIVO HOLDINGS INC WTS - PETVW STOCK NEWS

PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) has appointed Skylor Walker as the new field veterinary business development manager for Louisiana and southern Texas. Walker brings significant experience in veterinary sales, previously working with Contura International and ADP. She will focus on expanding sales of PetVivo's flagship product, Spryng™ with OsteoCushion™ Technology, a revolutionary injectable medical device for managing osteoarthritis and other musculoskeletal conditions in animals.

Spryng has shown effectiveness in improving medical outcomes for animals with lameness and joint-related afflictions. The product is now used by over 800 veterinary clinics across 50 states, with more than 10,000 Spryng syringes distributed nationwide. This success aligns with the projected growth of the U.S. animal health market, expected to reach $11.3 billion by 2030.

PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a provider of biomedical therapeutics for animals, was featured in the Sight & Sound's Visionaries Series on Bloomberg Television. The episode highlighted Spryng™ with OsteoCushion™ Technology, PetVivo's flagship product for managing osteoarthritis and other musculoskeletal conditions in animals. The program aired on September 5 and was distributed across various digital platforms, reaching a wide audience.

PetVivo CEO John Lai emphasized the transformative impact of Spryng on animal joint health. The company has achieved significant milestones, with Spryng now used in over 800 veterinary clinics across 50 states, resulting in the distribution of more than 10,000 Spryng syringes nationwide since its commercialization. This success aligns with the projected growth of the U.S. animal health market, expected to reach $11.3 billion by 2030.

PetVivo Holdings, Inc. (OTCQB: PETV) has appointed Dr. Kirsty Husby as senior technical services veterinarian to support the growing adoption of its flagship product, Spryng with OsteoCushion™ Technology. Dr. Husby, a board-certified veterinary surgeon with over a decade of experience, will help create broader understanding among veterinarians about Spryng's benefits in treating osteoarthritis in companion animals.

PetVivo recently achieved a significant milestone with Spryng being used by more than 800 veterinary clinics across 50 states, resulting in the distribution of over 10,000 Spryng syringes nationwide. This success has positioned the company to potentially double its revenue in the current fiscal year. Dr. Husby's appointment aims to further accelerate market adoption and improve the quality of life for animals living with osteoarthritis and other lameness issues.

PetVivo Holdings, Inc. (OTCQB: PETV & PETVW), a biomedical device company focusing on innovative medical devices for companion animals, has appointed Scot Cave as its new Field Veterinary Business Development Manager for the Northwest Region of the United States. Cave brings over 25 years of animal health sales and management experience to PetVivo, including leadership roles in the U.S. Army and positions with veterinary companies like Covetrus, Medivet, KindredBio, and Merck.

CEO John Lai expressed confidence that Cave's expertise will help PetVivo meet its primary objective of expanding sales. Cave, who holds a Bachelor of Science in Biology from Ferris State University, is enthusiastic about promoting Spryng, PetVivo's veterinary medical device that addresses joint-related afflictions by targeting cartilage loss or damage rather than just treating symptoms.

PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) has partnered with Orthobiologic Innovations (OBI) to advance clinical trials, product development, and marketing of Spryng™ with OsteoCushion™ Technology, their lead animal osteoarthritis medical device. Sherman O. Canapp, Jr. and Debra Canapp, OBI's leadership, have joined PetVivo's advisory board, bringing extensive experience in veterinary orthopedics and sports medicine.

OBI will assist PetVivo in coordinating clinical trials for Spryng, focusing on joint-related issues in canine patients' elbows and stifles (knees). These studies will evaluate the effectiveness of intra-articular injections of collagen-elastin hydrogel microparticles (CEHM) in dogs with osteoarthritis and those undergoing TPLO procedures. This collaboration aims to enhance product awareness and accelerate market adoption of Spryng across the United States.

PetVivo Holdings, Inc. (OTCB: PETV & PETVW), a biomedical device company focused on innovative medical devices for companion animals, has announced the appointment of Anthony Germinaro as its new Field Veterinary Business Development Manager for the Southwest Region of the United States. Germinaro brings over 14 years of experience in the animal health industry, including roles as a lead ultrasound technician and practice manager.

CEO John Lai expressed enthusiasm about Germinaro's addition to the team, highlighting his valuable in-clinic experience and potential to advance awareness of PetVivo's product Spryng™ with OsteoCushion™ technology. Germinaro's background includes work with notable entities such as Dr. Fossum's Pet Care, Anivive Life Sciences, and Banfield Pet Hospital.

PetVivo Holdings, Inc. (OTCQB: PETV) reported fiscal Q1 2025 results, reiterating guidance of 50% to 100% revenue growth for fiscal 2025. Key highlights:

• Revenues increased 6% to $124,000
• Gross profit up 6% to $111,000, maintaining 89.5% margin
• Net loss improved to $2.0 million or $(0.11) per share
• Distributor sales up 102% to $68,000
• Spryng™ used in over 800 veterinary clinics across 50 states
• Appointed new VPs of marketing and sales

The company expects fiscal 2025 revenue of $1.5 million to $2.0 million, representing 50% to 100% growth. PetVivo's focus remains on expanding Spryng™ adoption and distribution network.

PetVivo Holdings, Inc. (OTCQB: PETV & PETVW), a biomedical device company focused on innovative medical devices for companion animals, has appointed Eric Samples as its new Field Veterinary Business Development Manager for Ohio, Pennsylvania, and the Baltimore/DC area. Eric brings over 25 years of human and animal health sales experience to PetVivo, including roles at Covetrus, Sanofi Pharmaceuticals, and Fort Dodge Animal Health.

CEO John Lai expressed excitement about Eric's addition to the team, highlighting his valuable experience in advancing awareness of PetVivo's product Spryng™ with OsteoCushion™ technology. Eric, who holds a degree in Dairy and Animal Science from Penn State University, stated his enthusiasm for joining PetVivo and believes Spryng has the potential to improve medical outcomes for animals suffering from lameness and joint-related afflictions.

PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company specializing in innovative therapeutic medical devices for equines and companion animals, has announced its upcoming fiscal first quarter 2025 conference call. The call is scheduled for Wednesday, August 14, 2024, at 5:00 p.m. Eastern time. PetVivo management will host the presentation, which will be followed by a question-and-answer session.

Financial results for the quarter ended June 30, 2024, will be released in a press release prior to the call. Interested parties can join the call via a toll-free dial-in number or access the live webcast through the company's website. A replay of the webcast will be available after the conference call.